NCT06034860 is a Phase 1 clinical trial of MT-8421 in Non Small Cell Lung Cancer, sponsored by Molecular Templates, Inc..

Who is sponsoring NCT06034860?

NCT06034860 is sponsored by Molecular Templates, Inc..

What drugs are being tested in NCT06034860?

Interventions in NCT06034860: MT-8421, Nivolumab.

What condition does NCT06034860 study?

NCT06034860 studies Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma, Renal Cell Carcinoma, Microsatellite Instability High, Mismatch Repair Deficiency, Mesothelioma, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Cervical Cancer.

Is NCT06034860 still recruiting?

NCT06034860 is currently terminated. Last updated 1 November 2024.

Last reviewed 2024-11-01 · How we verify

NCT06034860

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Terminated Phase 1 Last updated 1 November 2024

What this trial tests

Phase 1 trial testing MT-8421 in Non Small Cell Lung Cancer in 15 participants. Terminated before completion.

Timeline

1 November 2023

Primary endpoint
31 October 2024

31 October 2024

Quick facts

Lead sponsor	Molecular Templates, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 November 2023
Primary completion	31 October 2024
Estimated completion	31 October 2024
Sites	5 locations across United States

Drugs / interventions tested

MT-8421 — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Melanoma — all drugs for Melanoma →
Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →

Sponsor

Molecular Templates, Inc. — full company profile →

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer or Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types. MT-8421 is an investigational drug that specifically targets and depletes cytotoxic T-lymphocytes-associated protein 4 (CTLA-4) expressing cells in an effort to directly dismantle the tumor microenvironment for the treatment of patients with advanced solid tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Insights in Molecular Therapies for Hepatocellular Carcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 5× · PMID 38791911 · DOI 10.3390/cancers16101831

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Molecular Templates, Inc. trials

Trials by the same sponsor.

NCT04795713 — Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 · Phase 1 · terminated
NCT04017130 — A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · terminated
NCT04029922 — Study of MT-5111 in HER2-positive Solid Tumors · Phase 1 · terminated
NCT03645395 — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for t · Phase 2 · terminated
NCT03488251 — PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06034860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Molecular Templates, Inc.
Last refreshed: 1 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06034860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing